{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:56:56Z","timestamp":1766023016846,"version":"3.48.0"},"reference-count":22,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/wfqm3371","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:38:31Z","timestamp":1710999511000},"page":"466-476","source":"Crossref","is-referenced-by-count":0,"title":["Clinical analysis of hairy cell leukemia: the rare indolent hematological malignancy"],"prefix":"10.62347","volume":"16","author":[{"given":"He","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood.V13.7.609.609","article-title":"Leukemic reticuloendotheliosis","volume":"13","author":"BA","year":"1958","unstructured":"Bouroncle BA, Wiseman BK and Doan CA. Leukemic reticuloendotheliosis. Blood 1958; 13: 609-630.","journal-title":"Blood"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1080\/10428194.2019.1608536","article-title":"Hairy cell leukemia: present and future directions","volume":"60","author":"Kreitman","year":"2019","unstructured":"Kreitman RJ. Hairy cell leukemia: present and future directions. Leuk Lymphoma 2019; 60: 2869-2879.","journal-title":"Leuk Lymphoma"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.6004\/jnccn.2017.0165","article-title":"2018, NCCN clinical practice guidelines in oncology","volume":"15","author":"Wierda","year":"2017","unstructured":"Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA and Sundar H. Hairy cell leukemia, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017; 15: 1414-1427.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL and Falini B. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017; 129: 553-560.","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Robak T, Matutes E, Catovsky D, Zinzani PL and Buske C; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5: v100-107.","DOI":"10.1093\/annonc\/mdv200"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/biom10081140","article-title":"Development of recombinant immunotoxins for hairy cell leukemia","volume":"10","author":"Kreitman","year":"2020","unstructured":"Kreitman RJ and Pastan I. Development of recombinant immunotoxins for hairy cell leukemia. Biomolecules 2020; 10: 1140.","journal-title":"Biomolecules"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/ajh.24936","article-title":"Hairy cell leukemia 2018: update on diagnosis, risk-stratification, and treatment","volume":"92","author":"Troussard","year":"2017","unstructured":"Troussard X and Cornet E. Hairy cell leukemia 2018: update on diagnosis, risk-stratification, and treatment. Am J Hematol 2017; 92: 1382-1390.","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bigorra L, Larriba I and Gutiérrez-Gallego R. The hairy cell leukaemia oxymoron: monocytotic monocytopenia. Clin Chem Lab Med 2020; 59: e111-e115.","DOI":"10.1515\/cclm-2020-0253"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","unstructured":"Saven A, Burian C, Koziol JA and Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926.","journal-title":"Blood"},{"key":"ref10","unstructured":"Kreitman RJ and Arons E. Update on hairy cell leukemia. Clin Adv Hematol Oncol 2018; 16: 205-215."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2147\/OTT.S242247","article-title":"Current and emerging therapeutic options for hairy cell leukemia variant","volume":"14","author":"Liu","year":"2021","unstructured":"Liu Q, Harris N, Epperla N and Andritsos LA. Current and emerging therapeutic options for hairy cell leukemia variant. Onco Targets Ther 2021; 14: 1797-1805.","journal-title":"Onco Targets Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MOH.0000000000000154","article-title":"Hairy cell leukemia: update and current therapeutic approach","volume":"22","author":"Salam","year":"2015","unstructured":"Salam L and Abdel-Wahab O. Hairy cell leukemia: update and current therapeutic approach. Curr Opin Hematol 2015; 22: 355-361.","journal-title":"Curr Opin Hematol"},{"key":"ref13","unstructured":"Wang TY, Li ZJ, Lyu R, Fu MW, Sui WW, Huang WY, Liu W, An G, Deng SH and Qiu LG. Clinical analysis of 24 patients of hairy cell leukemia treated by cladribine. Zhonghua Xue Ye Xue Za Zhi 2018; 39: 491-495."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial","volume":"174","author":"Chihara","year":"2016","unstructured":"Chihara D, Kantarjian H, OBrien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M and Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 2016; 174: 760-766.","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1182\/blood-2011-08-371989","article-title":"Fludarabine and rituximab for relapsed or refractory hairy cell leukemia","volume":"119","author":"AS","year":"2012","unstructured":"Gerrie AS, Zypchen LN and Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012; 119: 1988-1991.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC and Brown JR; Blood Cancer Research Partnership of the Leukemia & Lymphoma Society. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol 2019; 6: e419-e428.","DOI":"10.1016\/S2352-3026(19)30104-8"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1517\/13543784.2015.1081895","article-title":"Potential breakthroughs with investigational drugs for hairy cell leukemia","volume":"24","author":"Robak","year":"2015","unstructured":"Robak T, Wolska A and Robak P. Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opin Investig Drugs 2015; 24: 1419-1431.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","unstructured":"Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS and Giles F. Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia. Leukemia 2018; 32: 1768-1777.","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","unstructured":"Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B and Tallman MS. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 2015; 373: 1733-1747.","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-020-0328-z","article-title":"Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up","volume":"10","author":"Paillassa","year":"2020","unstructured":"Paillassa J, Cornet E, Noel S, Tomowiak C, Lepretre S, Vaudaux S, Dupuis J, Devidas A, Joly B, Petitdidier-Lionnet C, Haiat S, Mariette C, Thieblemont C, Decaudin D, Validire-Charpy P, Drenou B, Eisenmann JC, Uribe MO, Olivrie A, Touati M, Lambotte O, Hermine O, Karsenti JM, Feugier P, Vaillant W, Gutnecht J, Lippert E, Huysman F, Ghomari K, Boubaya M, Levy V, Riou J, Damaj G, Tanguy-Schmidt A, Hunault-Berger M and Troussard X. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J 2020; 10: 62.","journal-title":"Blood Cancer J"},{"key":"ref21","unstructured":"Wei C, Jin XX, Cai H, Wang X, Zhuang JL and Zhou DB. Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant. Zhonghua Nei Ke Za Zhi 2023; 62: 416-421."}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/2\/ajtr0154266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:07Z","timestamp":1766022727000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/2\/ajtr0154266.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/wfqm3371","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2024]]}}}